Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
PHASE1Active, not recruitingINTERVENTIONAL
Enrollment
10
Participants
Timeline
Start Date
November 7, 2022
Primary Completion Date
February 19, 2026
Study Completion Date
February 19, 2026
Conditions
Multiple System AtrophyMSA - Multiple System Atrophy
Interventions
BIOLOGICAL
hOMSC300
Human Oral Mucosa Stem Cells
Trial Locations (1)
Unknown
Tel-Aviv Sourasky Medical Center (Ichilov), Tel Aviv
All Listed Sponsors
lead
Cytora Ltd.
INDUSTRY
NCT05698017 - Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA) | Biotech Hunter | Biotech Hunter